German biotech BioNTech and U.S. drugmaker Pfizer Inc said on Monday they would begin a pivotal global study to evaluate their lead COVID-19 vaccine candidate.
FILE PHOTO: A woman holds a small bottle labeled with a"Vaccine COVID-19" sticker and a medical syringe in this illustration taken April 10, 2020. REUTERS/Dado Ruvic/File Photo
Patients are each given two doses of the drugmakers’ vaccine to help boost immunity, so the first 100 million doses would vaccinate around 50 million people. “The initiation of the Phase 2/3 trial is a major step forward in our progress toward providing a potential vaccine to help fight the ongoing COVID-19 pandemic,” said Kathrin Jansen, head of vaccine research and development at Pfizer.
Pfizer has already has an agreement to sell 100 million doses of its vaccine to the U.S. government and give it the option to buy 500 million more. It is in talks with other governments, including the European Union, about similar deals.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday
Weiterlesen »
Pfizer, BioNTech could submit vaccine for approval by Oct – latest updatesPfizer, BioNTech could submit vaccine for approval by October. Other Covid19 updates: 🌍 Virus-linked hunger tied to 10,000 child deaths a month 🇧🇴 Bolivian prisoners riot over virus exposure 🇰🇪 Kenya extends lockdown by 30 days More here:
Weiterlesen »
Moderna, Pfizer Coronavirus Vaccines Begin Final-Stage TestingTwo of the most advanced experimental vaccines entered the pivotal phase of their studies, with the first subjects receiving doses of Moderna vaccine and Pfizer preparing to inject participants in its trial.
Weiterlesen »
Stocks making the biggest moves after hours: Pfizer, F5 Networks, Virgin Galactic and moreSee which stocks are posting big moves after the bell.
Weiterlesen »
Moderna's COVID-19 vaccine candidate moves into late-stage trialModerna Inc said on Monday it has started a U.S. government-backed late-stage trial for its COVID-19 vaccine candidate, the first to be implemented under the Trump administration's Operation Warp Speed anti-coronavirus program.
Weiterlesen »
Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday
Weiterlesen »